Objective: High-dose chemotherapy (HDT) with autologous hematopoietic stem cell transplantation (tpx) improves long term outcome in patients with MM. We have evaluated the efficacy and toxicity of a sequential HDT including two cycles of melphalan 200 mg/m 2 in a multicenter trial.Materials and methods: Between 6/96 and 1/98, 140 patients with advanced MM (102 stage III and 38 stage II) were included at the time of best response to conventional polychemotherapy. 98 patients received mobilization therapy with high-dose cyclophosphamide (CY 7, 4 or 3 g/m 2 + 600 g/d G-CSF). In patients with cardiac diseases or amyloidosis, ifosfamide (IFO 12 g/m 2 ) was used instead. Interferon (IFN 3 × 4.5 Mio U per week) was administered 6 weeks post tpx as maintenance therapy Results: 128 patients (91%) were successfully harvested for tandem tpx (5.0 CD34+ cells/kg). 114 patients completed one tpx and 103 patients two tpx. 68 patients received IFN maintenance. 50 patients were evaluable for remission at day 100 after second tpx. 20 patients (40%) achieved a complete remission (EBMT criteria). Treatment related mortality occured with CY (IFO) in no patient, with the first tpx in 1 patient, and with the second tpx in no patient. Grade IV (WHO) non-hematological toxicity was observed in 5 patients. Progressive disease occured after CY (IFO) in 6 patients, after first tpx in 4 patients and until day 100 after second tpx in 1 patient.
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Conclusion:
We have demonstrated in a multicenter trial setting that tandem HDT is a safe and efficacious procedure for patients with MM under the age of 66 years. In a subsequent trial, we will compare the long-term outcome of patients who underwent one cycle versus two cycles of Melphalan. Primary systemic AL (amyloid light chain) amyloidosis ia a plasma cell disorder in which depositions of amyloid light chain protein cause progressive organ failure. The organs most commonly involved are the kidneys and the heart, but any other organ apart from the brain can be affected. The prognosis of primary amyloidosis is generally poor, with a median survival of one to two years. Therapeutic otpions for amyloidosis are limited. There is no available treatment which improves organ function by mobilization of the amyloid. But amyloidosis is a dynamic process, and measures which reduce the supply of the amyloid fibril precursor protein can result in a major regression of the deposits. Treatment of primary systemic amyloidosis with standard-dose melphalan results in low response rates and the response is slow. The remission rates with high-dose dexamethasonealone are low, but VAD has been shown to have considerable activity in AL amyloidosis. High-dose chemotherapy (HDCT) with autologous peripheral blood stem cell transplantation(PBSCT) can be performed to eradicate the plasma cell clone producing amyloidogenic proteins. Only the use of upfront-HDCT has been reported in primary amyloidosis so far. This treatment modality is effective but results in a high treatment-related mortality of about 20%.
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Here we report a new approach using VAD regimen with subsequent HDCT after achieving a remission. This approach, which resulted in an improvement of the patient's condition reported here before HDCT, might reduce the transplantation related morbidity and mortality in amyloidosis.
A 53-year old patient noticed the development of peripheral edema. A nephrotic syndrome due to primary amyloidosis was diagnosed by renal biopsy and other findings. During chemotherapy with conventional dose melphalan and prednisone, the proteinuria increased further to 9 g/24 h. Subsequently high-dose chemotherapy with PBSCT was considered. The patient received 4 courses of VAD repeated every 4 weeks. Under VAD, creatinine remained unchanged but the proteinuria improved rapidly (2.4 g/24 h after the forth cycle) and peripheral edema diminished. After chemotherapy with VAD, hematopoietic stem cells were mobilized with G-CSF. HDCT was performed using melphalan, 200 mg/m 2 . HDCT and PBSCT were tolerated well. One year after PBSCT renal function has improved further with diminished proteinuria of 1.0 g/24 h.
The patient has returned to work and is now in a good clinical condition without any complaints.
The use of VAD before HDCT, a standard approacch in multiple myeloma, may be useful in patients with primary AL amyloidosis for following reasons:
1. The chemotherapy with VAD may stop disease progression during the period until performing the HDCT. 2. The chemotherapy with VADmay lead to an improvement of the condition of the patient before HDCT and S9 thereby reduce the transplantation related morbidity and mortality. 3. Upfront chemotherapy before peripheral stem cell harvest can reduce the number of circulating clonogenic cells, and thereby the contamination of the leukapheresis product.
On the basis of these ideas, a multicenter trial has now been planned in Germany using VAD induction followed by HDCT using melphalan with PBSCT as consolidation treatment.
